Loading...
XSHE300583
Market cap553mUSD
Jan 10, Last price  
21.41CNY
1D
-6.59%
1Q
-10.53%
IPO
-46.33%
Name

Shandong Sito Bio-technology Co Ltd

Chart & Performance

D1W1MN
XSHE:300583 chart
P/E
89.06
P/S
3.17
EPS
0.24
Div Yield, %
0.79%
Shrs. gr., 5y
11.29%
Rev. gr., 5y
3.99%
Revenues
1.28b
-2.46%
11,031,565283,587,947521,011,426668,166,780568,245,934785,566,4581,052,277,111965,800,380913,187,6041,202,622,7031,312,111,8431,279,783,092
Net income
46m
+8.67%
041,561,599165,754,384187,044,570101,176,69092,001,754126,848,54555,309,472036,205,36041,967,41345,603,990
CFO
-93m
L
-30,504,10024,949,239174,489,33187,103,73280,146,75510,896,249057,616,516254,600,648227,349,328145,335,684-92,845,545
Dividend
Jul 30, 20240.45 CNY/sh
Earnings
Jun 20, 2025

Profile

Shandong Sito Bio-technology Co., Ltd. researches and develops new steroid hormones, intermediates, and derivatives. Its products include 9a-hydroxyandrostenedione, 17a-hydroxyprogesterone, 17a-hydroxy progesterone derivatives, anecort acetate, dexamethasone epoxy hydrolysate, progesterone intermediate, opener, tetraene, androstenedione, ketal, acid removal, 3-ketal, and betamethasone epoxy hydrolyzate, as well as 1,4-androstenedione. The company was founded in 2002 and is based in Heze, China.
URL
https://www.sitobiotech.com/
IPO date
Jan 06, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,279,783
-2.46%
1,312,112
9.10%
Cost of revenue
1,114,756
1,141,387
Unusual Expense (Income)
NOPBT
165,027
170,725
NOPBT Margin
12.89%
13.01%
Operating Taxes
4,932
5,433
Tax Rate
2.99%
3.18%
NOPAT
160,094
165,292
Net income
45,604
8.67%
41,967
15.91%
Dividends
(32,284)
(1,604)
Dividend yield
0.90%
0.07%
Proceeds from repurchase of equity
(1,157)
(1)
BB yield
0.03%
0.00%
Debt
Debt current
627,006
576,244
Long-term debt
122,854
124,716
Deferred revenue
24,548
15,164
Other long-term liabilities
47,123
1
Net debt
446,250
449,361
Cash flow
Cash from operating activities
(92,846)
145,336
CAPEX
(94,059)
Cash from investing activities
(103,781)
Cash from financing activities
319,769
FCF
(162,585)
131,525
Balance
Cash
238,491
188,398
Long term investments
65,120
63,200
Excess cash
239,621
185,993
Stockholders' equity
695,821
663,083
Invested Capital
2,640,100
2,288,089
ROIC
6.50%
7.30%
ROCE
5.73%
6.90%
EV
Common stock shares outstanding
182,416
171,075
Price
19.74
38.62%
14.24
-7.71%
Market cap
3,600,891
47.81%
2,436,112
-7.71%
EV
4,100,431
2,936,214
EBITDA
338,596
333,956
EV/EBITDA
12.11
8.79
Interest
40,864
36,886
Interest/NOPBT
24.76%
21.61%